Speakers: ELAN TRIAL, Chairman Department of Neurology, University Hospital Basel, Urs Fischer
ELAN TRIAL: The optimal timing for DOAC initiation after acute ischaemic stroke is unclear. An early start may increase the risk of intracranial hemorrhage whereas a late start may increase the risk of early stroke recurrence. We performed an open label multicenter, randomised, to-arm, accessor-blinded trial at 103 sites in 15 different countries. And we randomised more than 2000 patients. An early start was within 48 hours of minor or moderate stroke or day 6 to 7 following major stroke. A late start at day 3 to 4 following minor day 6 to 7, following moderate or day 12 to 14, following major stroke. Our ELAN trial will estimate the safety and efficacy of early initiation of DOACs compared to later guideline based initiation using imaging selection in people with acute ischaemic stroke and atrial fibrillation. We are keen to present our data at ESOC 2023 in Munich and we hope that ELAN will bring more evidence when DOACs after an acute ischaemic stroke can be started.
.png)